Esperion Therapeutics, Inc.ESPRNASDAQ

Overview Intelligence Charts News Fundamentals Key Metrics Earnings Growth Financials Insiders

Latest News

defenseworld.net

Esperion Therapeutics Touts 38% Revenue Growth, Corstasis Deal and 2026 Cash-Gen Path at Conference

Executives from Esperion Therapeutics (NASDAQ: ESPR) highlighted accelerating revenue growth, plans to expand its commercial footprint, and details of a pending acquisition during remarks at the Citizens Life Sciences Conference in Miami, coming a day after the company reported earnings. 2025 results and momentum entering 2026 Chief Executive Officer Sheldon Koenig said Esperion delivered what he

globenewswire.com

Esperion's Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia

– Bempedoic Acid Receives Strongest Endorsement from AHA/ACC Multisociety Guideline for Patients with Statin Intolerance and in Primary and Secondary Prevention Patients with Severe Hypercholesterolemia –

defenseworld.net

Brokerages Set Esperion Therapeutics, Inc. (NASDAQ:ESPR) Target Price at $8.25

Shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eight analysts that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, five have issued a buy

zacks.com

ESPR's Q4 Earnings Lag Estimates, Revenues Beat, Stock Down

Esperion Therapeutics' Q4 revenues surge 144% to $168.4M but EPS of 22 cents misses estimates. Shares fall as mixed results weigh on sentiment.

seekingalpha.com

Esperion Therapeutics, Inc. (ESPR) Q4 2025 Earnings Call Transcript

zacks.com

Esperion Therapeutics (ESPR) Misses Q4 Earnings Estimates

Esperion Therapeutics (ESPR) came out with quarterly earnings of $0.22 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to a loss of $0.1 per share a year ago.

globenewswire.com

Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

– FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million –

zacks.com

ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M

Esperion to buy Corstasis for $75M in cash, adding FDA-approved Enbumyst nasal spray to its cardiovascular franchise. The deal is likely to be closed in Q2.

seekingalpha.com

Esperion Therapeutics, Inc. (ESPR) M&A Call Transcript

feeds.benzinga.com

Esperion Acquires Enbumyst Maker Corstasis

Esperion (ESPR) shares dip premarket after announcing a $75M deal to buy Corstasis Therapeutics, adding FDA-approved nasal spray Enbumyst.

globenewswire.com

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

– Enbumyst ™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion's Established Cardiovascular Commercial Infrastructure, Synergistically Expand Product Portfolio and Accelerate Double-Digit Revenue Growth –

businesswire.com

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

ANN ARBOR, Mich. & HENDERSON, Nev.--(BUSINESS WIRE)-- #CHF--Esperion (NASDAQ: ESPR) and Corstasis Therapeutics Inc., a privately-held, commercial-stage biopharmaceutical company advancing innovative outpatient therapies for the treatment of edema associated with cardiovascular, and hepatic and renal disease, today announced they have entered into a definitive agreement for Esperion to acquire Corstasis. Under the terms of the agreement, Esperion will acquire Corstasis, which developed and is commercia.

zacks.com

Esperion Therapeutics (ESPR) Earnings Expected to Grow: Should You Buy?

Esperion Therapeutics (ESPR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

defenseworld.net

Principal Financial Group Inc. Trims Stake in Esperion Therapeutics, Inc. $ESPR

Principal Financial Group Inc. lessened its position in shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) by 51.7% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The firm owned 190,056 shares of the biopharmaceutical company's stock after selling 203,234 shares during the quarter. Principal Financial Group

globenewswire.com

Esperion to Participate in The 2026 Citizens Life Sciences Conference

ANN ARBOR, Mich., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2026 Citizens Life Sciences Conference on March 11, 2026, at 8:25 a.m. ET.

globenewswire.com

Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040

ANN ARBOR, Mich., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem). This agreement resolves the patent litigation brought by Esperion against Alkem in response to Alkem's Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of NEXLETOL and NEXLIZET prior to the expiration of the applicable patents. Pursuant to the agreement, Alkem has agreed not to market a generic version of either NEXLETOL or NEXLIZET in the United States prior to April 19, 2040, unless certain limited circumstances customarily included in these types of agreements occur.

defenseworld.net

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of “Moderate Buy” from Analysts

Esperion Therapeutics, Inc. (NASDAQ: ESPR - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seven brokerages that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, four have given a buy rating and one

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

globenewswire.com

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance